Is galectin-3 a promoter of ventricular dysfunction?
Heart failure is nowadays a common condition associated with high mortality and increased healthcare-related costs. Over the years, the research on heart failure management has been extensive in order to better diagnose and treat the condition. Since the progression of left ventricular dysfunction i...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2018-01-01
|
| Series: | Romanian Journal of Laboratory Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/rrlm-2018-0001 |
| _version_ | 1819147966505549824 |
|---|---|
| author | Lupu Adrian Lupu Silvia Agoston-Coldea Lucia |
| author_facet | Lupu Adrian Lupu Silvia Agoston-Coldea Lucia |
| author_sort | Lupu Adrian |
| collection | DOAJ |
| description | Heart failure is nowadays a common condition associated with high mortality and increased healthcare-related costs. Over the years, the research on heart failure management has been extensive in order to better diagnose and treat the condition. Since the progression of left ventricular dysfunction is a consequence of myocardial inflammation, apopotosis, and fibrosis leading to myocardium remodelling, several molecules that are involved in the inflammation pathways have been explored as possible biomarkers for the condition. The study of biomarkers and their key roles in inflammation could allow early identification of patients with heart failure, improve prognostic assessment, and provide a target for future therapies. Among currently studied biomarkers, extensive research has been conducted on galectin-3, a galactoside-binding lectin, which is synthetised and secreted when cardiomyocytes and fibroblasts are submitted to mechanical stress. Accordingly, it has been hypothesised that galectin-3 could be a promoter of left ventricular dysfunction. Galectin-3 has been shown to mediate inflammation by several different pathways which are further detailed in the current review. Also, we aimed to provide a comprehensive overview of existing evidence on the utility of galectin-3 in clinical settings associated with heart failure. |
| first_indexed | 2024-12-22T13:38:13Z |
| format | Article |
| id | doaj.art-41ee9904b0bc4b008ebd6fe8ff15b30f |
| institution | Directory Open Access Journal |
| issn | 2284-5623 |
| language | English |
| last_indexed | 2024-12-22T13:38:13Z |
| publishDate | 2018-01-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Romanian Journal of Laboratory Medicine |
| spelling | doaj.art-41ee9904b0bc4b008ebd6fe8ff15b30f2022-12-21T18:23:59ZengSciendoRomanian Journal of Laboratory Medicine2284-56232018-01-01261213610.2478/rrlm-2018-0001rrlm-2018-0001Is galectin-3 a promoter of ventricular dysfunction?Lupu Adrian0Lupu Silvia1Agoston-Coldea Lucia2Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, RomaniaUniversity of Medicine and Pharmacy of Tirgu Mures, Tirgu Mures, Romania2nd Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, RomaniaHeart failure is nowadays a common condition associated with high mortality and increased healthcare-related costs. Over the years, the research on heart failure management has been extensive in order to better diagnose and treat the condition. Since the progression of left ventricular dysfunction is a consequence of myocardial inflammation, apopotosis, and fibrosis leading to myocardium remodelling, several molecules that are involved in the inflammation pathways have been explored as possible biomarkers for the condition. The study of biomarkers and their key roles in inflammation could allow early identification of patients with heart failure, improve prognostic assessment, and provide a target for future therapies. Among currently studied biomarkers, extensive research has been conducted on galectin-3, a galactoside-binding lectin, which is synthetised and secreted when cardiomyocytes and fibroblasts are submitted to mechanical stress. Accordingly, it has been hypothesised that galectin-3 could be a promoter of left ventricular dysfunction. Galectin-3 has been shown to mediate inflammation by several different pathways which are further detailed in the current review. Also, we aimed to provide a comprehensive overview of existing evidence on the utility of galectin-3 in clinical settings associated with heart failure.https://doi.org/10.2478/rrlm-2018-0001galectin-3biomarkerheart failuredyspneaventricular dysfunctionventricular remodelling |
| spellingShingle | Lupu Adrian Lupu Silvia Agoston-Coldea Lucia Is galectin-3 a promoter of ventricular dysfunction? Romanian Journal of Laboratory Medicine galectin-3 biomarker heart failure dyspnea ventricular dysfunction ventricular remodelling |
| title | Is galectin-3 a promoter of ventricular dysfunction? |
| title_full | Is galectin-3 a promoter of ventricular dysfunction? |
| title_fullStr | Is galectin-3 a promoter of ventricular dysfunction? |
| title_full_unstemmed | Is galectin-3 a promoter of ventricular dysfunction? |
| title_short | Is galectin-3 a promoter of ventricular dysfunction? |
| title_sort | is galectin 3 a promoter of ventricular dysfunction |
| topic | galectin-3 biomarker heart failure dyspnea ventricular dysfunction ventricular remodelling |
| url | https://doi.org/10.2478/rrlm-2018-0001 |
| work_keys_str_mv | AT lupuadrian isgalectin3apromoterofventriculardysfunction AT lupusilvia isgalectin3apromoterofventriculardysfunction AT agostoncoldealucia isgalectin3apromoterofventriculardysfunction |